Manas AI is at the forefront of revolutionizing drug discovery through the integration of proprietary artificial intelligence and generative computational chemistry. By leveraging advanced AI filters and bespoke chemical libraries, the company aims to identify high-potential therapeutic candidates with unprecedented speed and accuracy. Their partnership with Microsoft enhances this capability, utilizing Azure cloud infrastructure to achieve molecular docking speeds that are 100 times faster than traditional methods. This technological synergy allows Manas AI to significantly reduce the timeline and costs associated with therapeutic discovery, particularly in the treatment of aggressive cancers and rare diseases.

A key initiative of Manas AI is Project Cosmos, which seeks to map the fundamental "rules" of drug binding, further accelerating the discovery of novel chemical entities. The company combines the expertise of renowned scientists, including Nobel laureates and members of prestigious scientific academies, with advanced AI systems to explore chemical spaces and analyze molecular interactions. This collaborative approach not only aims to expedite the drug development process from years to mere months but also enhances the likelihood of successful outcomes, ultimately bringing life-saving treatments to patients more swiftly.

United States

Manas AI is a full-stack, AI-driven drug discovery company. By harnessing the power of proprietary AI models and leveraging extensive computational infrastructure, the company aims to dramatically reduce drug discovery timelines. Co-founded by Dr. Siddhartha Mukherjee and Reid Hoffman, and a world-class interdisciplinary team that spans AI, computational chemistry, biology, and clinical research, Manas AI is on a mission to bring life-saving treatments to patients faster than ever before.

Manas AI

Company Details